JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2006; 47:13-17, doi:10.1016/j.jacc.2006.04.013
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ambrose, J. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ambrose, J. A.

Myocardial Ischemia and Infarction

John A. Ambrose, MD, FACC*

UCSF-Fresno, Fresno, California.


Figure 1
View larger version (12K):

[in a new window]
  		Figure 1 Acute Catheterization and Urgent Intervention Triage Strategy Trial (ACUITY): 30-day composite net clinical benefit (death, myocardial infarction, revascularization for ischemia, or major bleeding), showing superiority of bivalirudin alone versus heparin plus glycoprotein (GP) IIb/IIIa inhibitors (p = 0.015). Combination of bivalirudin and GP IIb/IIIa inhibitors was noninferior to heparin plus GP IIb/IIIa inhibitors.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2006 by the American College of Cardiology Foundation.